Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED)

Atsushi Tanaka; Yosuke Okada; Keiichi Torimoto; Nozomu Kamei; Hiroyuki Hirai; Teruyuki Kono; Kazuhiro Sugimoto; Hiroki Teragawa; Isao Taguchi; Tatsuya Maruhashi; Satomi Sonoda; Akira Kurozumi; Saori Inagaki; Chikage Oshita; Itaru Hisauchi; Kanae Takahashi; Yukihito Higashi; Michio Shimabukuro; Koichi Node; PROCEED Trial Investigators

doi:10.1016/j.diabet.2023.101447

Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED)

Diabetes Metab. 2023 Jul;49(4):101447. doi: 10.1016/j.diabet.2023.101447. Epub 2023 Apr 26.

Authors

Atsushi Tanaka¹, Yosuke Okada², Keiichi Torimoto², Nozomu Kamei³, Hiroyuki Hirai⁴, Teruyuki Kono⁵, Kazuhiro Sugimoto⁶, Hiroki Teragawa⁷, Isao Taguchi⁸, Tatsuya Maruhashi⁹, Satomi Sonoda¹⁰, Akira Kurozumi¹⁰, Saori Inagaki¹¹, Chikage Oshita¹², Itaru Hisauchi¹³, Kanae Takahashi¹⁴, Yukihito Higashi¹⁵, Michio Shimabukuro¹⁶, Koichi Node¹⁷; PROCEED Trial Investigators

Affiliations

¹ Department of Cardiovascular Medicine, Saga University, Saga, Japan. Electronic address: tanakaa2@cc.saga-u.ac.jp.
² First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
³ Department of Endocrinology and Metabolism, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Hiroshima, Japan.
⁴ Department of Internal Medicine, Shirakawa Kosei General Hospital, Shirakawa, Japan.
⁵ Department of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University School of Medicine, Fukushima, Japan.
⁶ Diabetes Center, Ohta Nishinouchi Hospital, Koriyama, Japan.
⁷ Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan.
⁸ Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
⁹ Department of Regenerative Medicine, Hiroshima University, Hiroshima, Japan.
¹⁰ First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
¹¹ Department of Endocrinology and Metabolism, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Hiroshima, Japan.
¹² Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan.
¹³ Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
¹⁴ Department of Biostatistics, Hyogo Medical University, Nishinomiya, Japan.
¹⁵ Department of Regenerative Medicine, Hiroshima University, Hiroshima, Japan.
¹⁶ Department of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University School of Medicine, Fukushima, Japan.
¹⁷ Department of Cardiovascular Medicine, Saga University, Saga, Japan. Electronic address: node@cc.saga-u.ac.jp.

PMID: 37116858
DOI: 10.1016/j.diabet.2023.101447

No abstract available

Publication types

Randomized Controlled Trial
Letter

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 2* / chemically induced
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucosides / therapeutic use
Humans
Hypoglycemic Agents / therapeutic use
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy

Substances

ipragliflozin
Hypoglycemic Agents
Glucosides
Blood Glucose